CD19 and acute lymphoblastic leukemia: CAR-T therapies targeting B-cell antigens such as CD19 and CD20 have shown remarkable clinical efficacy, leading to durable remissions in patients with otherwise refractory or relapsed B-cell malignancies, including acute lymphoblastic leukaemia (ALL), diffuse large B-cell lymphoma, and chronic lymphocytic leukaemia [45, 46].